Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells

Jennifer Varin 1 Laury Poulain 2 Mikael Hivelin 3 Patrick Nusbaum 4 Arnaud Hubas 4 Ingrid Laurendeau 1 Laurent Lantieri 3 Pierre Wolkenstein 5, 6 Michel Vidaud 1, 4 Eric Pasmant 1, 4 Nicolas Chapuis 2, 7 Béatrice Parfait 1, 4, *
* Auteur correspondant
1 EA 7331 - Génétique, physiopathologie et approches thérapeutiques des maladies héréditaires du système nerveux
2 UM3 (UMR 8104 / U1016) - Institut Cochin
3 Service de Chirurgie plastique, reconstructrice et esthétique [Pompidou]
4 Service de Biochimie et de Génétique Moléculaire
5 LIC - Laboratoire d'Investigation Clinique
6 Département de dermatologie
7 Service d’Hématologie Biologique
Abstract : Approximately 30-50% of individuals with Neurofibromatosis type 1 develop benign peripheral nerve sheath tumors, called plexiform neurofibromas (PNFs). PNFs can undergo malignant transformation to highly metastatic malignant peripheral nerve sheath tumors (MPNSTs) in 5-10% of NF1 patients, with poor prognosis. No effective systemic therapy is currently available for unresectable tumors. In tumors, the NF1 gene deficiency leads to Ras hyperactivation causing the subsequent activation of the AKT/mTOR and Raf/MEK/ERK pathways and inducing multiple cellular responses including cell proliferation. In this study, three NF1-null MPNST-derived cell lines (90-8, 88-14 and 96-2), STS26T sporadic MPNST cell line and PNF-derived primary Schwann cells were used to test responses to AZD8055, an ATP-competitive "active-site" mTOR inhibitor. In contrast to rapamycin treatment which only partially affected mTORC1 signaling, AZD8055 induced a strong inhibition of mTORC1 and mTORC2 signaling in MPNST-derived cell lines and PNF-derived Schwann cells. AZD8055 induced full blockade of mTORC1 leading to an efficient decrease of global protein synthesis. A higher cytotoxic effect was observed with AZD8055 compared to rapamycin in the NF1-null MPNST-derived cell lines with IC50 ranging from 70 to 140 nM and antiproliferative effect was confirmed in PNF-derived Schwann cells. Cell migration was impaired by AZD8055 treatment and cell cycle analysis showed a G0/G1 arrest. Combined effects of AZD8055 and PD0325901 MEK inhibitor as well as BRD4 (BromoDomain-containing protein 4) inhibitors showed a synergistic antiproliferative effect. These data suggest that NF1-associated peripheral nerve sheath tumors are an ideal target for AZD8055 as a single molecule or in combined therapies.
Type de document :
Article dans une revue
Oncotarget, Impact journals, 2016, 7 (24), pp.35753-35767. 〈10.18632/oncotarget.7099〉
Liste complète des métadonnées

Littérature citée [49 références]  Voir  Masquer  Télécharger
http://www.hal.inserm.fr/inserm-01399312
Contributeur : Mireille Bos <>
Soumis le : vendredi 18 novembre 2016 - 16:00:08
Dernière modification le : mercredi 29 août 2018 - 01:10:33
Document(s) archivé(s) le : mardi 21 mars 2017 - 03:12:03

Fichier

7099-107834-4-PB.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Collections

UPEC-UPEM | UNIV-PARIS5 | USPC

Citation

Jennifer Varin, Laury Poulain, Mikael Hivelin, Patrick Nusbaum, Arnaud Hubas, et al.. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells. Oncotarget, Impact journals, 2016, 7 (24), pp.35753-35767. 〈10.18632/oncotarget.7099〉. 〈inserm-01399312〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

209

Téléchargements de fichiers

80

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD